Bio-Techne (NASDAQ: TECH) reported Q4 EPS of $0.92, $0.04 worse than the analyst estimate of $0.96. Revenue for the quarter came in at $134.8 million versus the consensus estimate of $129.23 million.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.